Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Hepatitis B affects almost 300 million people worldwide ... which reported phase 2 data at the AASLD conference last year, and Arrowhead Pharma’s antisense oligonucleotide ARO-HBV.

The trial, which focuses on chronic hepatitis B (cHBV), shows potential advancements in treatment options for the disease. The latest findings involve Group C participants who received a ...

Common causes of this include hepatitis B and C, NAFLD, and alcoholic liver ... the American Association for the Study of Liver Diseases (AASLD) recommends annual screening for people at high ...

“We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing ... of Liver Diseases (AASLD) – The Liver ...

Common causes of this include hepatitis B and C, NAFLD, and alcoholic liver disease ... Because of this, the American Association for the Study of Liver Diseases (AASLD) recommends annual screening ...

The inclusion criteria specified patients diagnosed with HCC either pathologically or according to the American Association for the Study of Liver Diseases (AASLD) practice guidelines ... were male.

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...